SCHEMBL4263053

SCHEMBL4263053

O=C(NOCC(F)(F)F)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 2/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ PLOD2 O00469 2/20 0.52
▸ PLOD3 O60568 1/20 0.52
▸ PLOD1 Q02809 1/20 0.52
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ TSHR P16473 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ TP53 P04637 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ LMNA P02545 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ ROCK2 O75116 1/20 0.48
▸ ROCK1 Q13464 1/20 0.48
▸ ALDH1A1 P00352 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27959806 0.81 NPC1 (0.59) HDAC1HDAC6KMT2ANPC1RAB9A
SCHEMBL20916923 0.80 HDAC1 (0.57) HDAC1HDAC6THRBPLOD2PLOD3
SCHEMBL9565915 0.80 ALDH1A1 (0.59) HDAC1HDAC6THRBMEN1KMT2A
SCHEMBL25271022 0.78 ALDH1A1 (0.57) HDAC1HDAC6THRBMEN1KMT2A
SCHEMBL27623338 0.78 PLOD2 (0.57) HDAC1HDAC6THRBPLOD2PLOD3
SCHEMBL27604518 0.77 LMNA (0.59) THRBPLOD2PLOD3PLOD1MEN1
SCHEMBL29549978 0.77 THRB (0.66) HDAC1HDAC6THRBPLOD2PLOD3
SCHEMBL1116605 0.77 THRB (0.66) HDAC1HDAC6THRBPLOD2PLOD3
SCHEMBL8382795 0.77 GAA (0.53) HDAC1HDAC6THRBPLOD2MEN1
SCHEMBL8483607 0.77 RAB9A (0.71) HDAC1HDAC6PLOD2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701658-B2 Amide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2017-07-11 — — US disclosed
CN-106661043-A 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives 豪夫迈·罗氏有限公司 2017-05-10 — — CN disclosed
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2015-04-16 — — US disclosed
EP-2044055-A2 AMIDE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2009-04-08 — — EP disclosed
WO-2008011131-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105393-A1 AMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN5A, SCN1A HDAC1 282/4885HDAC6 198/4885THRB 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback